KR100375342B1 - A natural antimicrobial agents for the improvement of gastrointestinal disease. - Google Patents

Abstract

(1) The technical field to which the invention described in the claims belongs

It relates to a natural antimicrobial composition for improving gastrointestinal diseases.

(2) The technical problem to be solved by the invention

Gastrointestinal diseases such as gastric ulcer and duodenal ulcer have been identified as a major cause of bacteria called Helicobacter pylori. Antibiotics used to treat gastrointestinal diseases effectively inhibit the growth of Helicobacter pylori but are difficult to use for a long time and carry the risk of antibiotic misuse and antibiotic resistance. Gastrointestinal disease is also difficult to treat ulcers because it is easily recurred by Helicobacter pylori even once treated. Bacteriocin is a natural antibacterial substance produced by microorganisms and has a merit that does not accumulate in the human body because it is a natural protein component.

The present invention is to provide a natural antimicrobial composition effective in improving and treating gastrointestinal diseases by using the inhibitory effect of the bacteriocin produced by lactic acid bacteria bacteriocin growth Helicobacter pylori.

(3) Summary of the solution method of the invention

The present invention provides a bacteriocin-producing natural antibacterial substance composition using bacteriocin, characterized in that it contains 0.01-10.0% by weight of a bacteriocin-producing strain culture or 0.1-300ppm of bacteriocin produced by these strains. Culture composition 0.01-10.0% by weight of Lactis subspisis Lactis A164 (strain of Patent Application No. 98-40669, pending patent application No. 98-40669 by the same applicant) or 0.1 bacteriocin produced by these strains It provides a natural antibacterial substance composition and a method for producing a gastrointestinal disorder containing -300ppm.

(4) Important uses of the invention

Gastrointestinal disease improvement natural antibacterial substance composition according to the present invention can be used as a dietary supplement or pharmaceutical preparations that can improve or treat the gastrointestinal diseases caused by Helicobacter pylori bacteria.

Description

A natural antimicrobial agents for the improvement of gastrointestinal disease.

The present invention relates to the effect of improving gastrointestinal diseases using bacteriocin, a natural antimicrobial material that can be used as a food preservation or biocontrol agent. The bacteriocin is a similar form by several researchers since Davis et al. Discovered a protein substance that inhibits the growth of microorganisms from Escherichia coli in 1925 and named this protein colicin. Has been reported as a proteinaceous substance. These bacteriocins consistently have a narrow antimicrobial range limited to strains that are closely related to the antimicrobial producing strain itself and to lineage and lineage, and have similar characteristics to antibiotics.

Because bacteriocin molecules are composed of proteins, they are decomposed by protein hydrolase in the digestive system as soon as they are ingested in the human body. Therefore, they are expected to be useful as new bio-preservatives for foods or biocontrol agents for fermented foods. It is becoming.

Lactic acid bacteria are microorganisms that produce lactic acid using anaerobic carbohydrates and are widely distributed in nature. Lactic acid bacteria improve the preservation of foods by reducing the pH by several kinds of organic acids, their metabolites, because organic acids such as lactic acid and acetic acid have bactericidal action against most microorganisms. In addition to organic acids, hydrogen peroxide and the bacteriocins they produce are involved in preservation. Nisin, the most widely known bacteriocin produced by lactic acid bacteria, has long been allowed for use due to its broad antimicrobial range, and in 1988, the Food and Drug Safety Division (FDA) in the United States gave GRAS (generally recognized as safe). It was recognized as a food additive.

For this known nisin, there have been reports of using as a bactericide using a composition containing a chelating agent and a surfactant, or as a bactericide using bacteriocin such as lyostatin produced by the nisin and the Staphylococcus microorganism. . In addition, some researchers have developed an oral hygiene composition using bacteriocin by using the effect of inhibiting Streptococcus mutans, a causative agent of caries.

Digestive gastrointestinal diseases, such as gastric ulcer and duodenal ulcer, are now more easily seen by modern people who have weakened immune function due to stress and environmental pollution. More than 80% have reported or have had the disease in the past. One of the characteristics of these gastrointestinal diseases is that once an ulcer develops, the disease easily recurs even after treatment, and reports that the recurrence rate reaches 90%. This is because the main cause of ulcers is caused by a Gram-negative bacterium called Helicobacter pylori, which is difficult to cure and also recursed by the growth of the bacterium. It is a reality.

Helicobacter pylori is a bacterium that lives primarily in the stomach and duodenum, and secretes urease. Clinically, in order to confirm the presence of this bacterium, a method of confirming the presence of Helicobacter pylori bacteria by measuring the presence of urease activity is used, and a measurement kit is commercially available.

It has been confirmed that gastroenteritis such as gastritis and gastric ulcer are caused by infection of Helicobacter pylori in various aspects. In other words, patients with gastrointestinal diseases infected with Helicobacter pylori have higher ammonia concentrations than non-infected patients. This ammonia alkalines the gastric mucosa, causing gastric acid in the lumen to flow back into the epithelial cells, resulting in gastric mucosal damage that triggers gastric ulcers. In addition, ammonia produced by urease can be directly cytotoxic, resulting in damage to the gastric mucosa. In addition, the ammonia produced promotes gastrin production in the gastric pyloric mucosa, and accordingly, gastric acid secretion is excessive in the cells, thereby triggering gastric ulceration.

To treat peptic ulcers, pharmaceuticals such as the use of H ₂ receptor antagonists such as Cimetidine, Ranitidine, or inhibiting gastric secretion, such as Aluminum, Sucralfate, Prostaglandin, Bismuth, or neutralizing hormones, immune system stimulation, or bicarbonate ions I'm using. In addition, antibiotics such as Metronidazole, Amoxicillin, and Clarithromycin are used in parallel to directly remove Helicobacter pylori, a bacterium that causes ulcer disease or recurrent disease.

However, these side effects can occur through pharmaceuticals such as gastric secretion inhibitors or antibiotics. In addition to diarrhea, indigestion, and decreased bowel movements, side effects such as anxiety, depression, and hallucinations have been reported, and even serious cases such as renal function suppression and hematopoietic disorders. Moreover, there are many problems such as antibiotic resistance to take long-term to properly respond to high recurring gastrointestinal diseases.

Recently, in order to overcome the side effects of such pharmaceuticals, various plant extracts such as aloe, whitening, creation, cabbage, herbal medicines, etc. have been used, but there is no lack of scientific background, such as the identification of specific substances by simple extracts. not.

Therefore, in the present invention, it was confirmed that bacteriocin, a natural antibacterial substance produced by lactic acid bacteria, effectively inhibits Helicobacter pylori, which causes gastrointestinal diseases, and a composition having no side effects even when taken for a long time with gastrointestinal diseases through its proper composition. Was done. Accordingly, to provide a gastrointestinal disease-improving natural antibacterial substance composition containing 0.01-10.0% by weight of the culture containing bacteriocin produced by lactic acid bacteria.

In more detail, an object of the present invention is a 0.01-10.0% by weight of a bacteriocin-producing strain culture or 0.1-300 ppm of the bacteriocins produced by these strains, more specifically, Lactococcus lactis subspirosis Lactis A164 (by the same applicant in Korea Patent Application No. 98-40669 pending patent application No. No. KFCC 11047 strain) culture medium 0.01-10.0% by weight or providing a natural antimicrobial composition for improving gastrointestinal diseases containing 0.1-300ppm of bacteriocin produced by these strains will be. The bacteriocins produced by Lactococcus lactis subcipisis lactis A164, the main component of the composition, have antimicrobial activity as compared to conventional known bacteriocins, such as niacin or niacin-producing strains. It was confirmed that the superiority, in particular against the Helicobacter pylori bacteria was also confirmed the antimicrobial activity of the comparative advantage.

The composition according to the present invention may contain a mixture of natural antimicrobial substances or antibiotics that can be used as additives to increase the antimicrobial effect. Natural antibacterial substances include grapefruit seed extract, chitosan, tea tree oil, green tea extract, and the like, and may contain 5-50% by weight within the effective content of bacteriocin. In addition, by mixing the antibiotics Metronidazole, Amoxicillin, Clarithromycin, etc., which are used to inhibit Helicobacter pylori in 5-50% by weight within the effective content of bacteriocin, the amount of antibiotics can be reduced to minimize the side effects of taking antibiotics. .

In addition, the bacteriocin composition according to the present invention may include preparing the composition in granules, capsules, tablets, syrups, liquid forms using acceptable carriers or substrates known in pharmacy to efficiently function in the gastrointestinal tract.

Now, the present invention will be described in more detail with reference to the following examples, but are not intended to limit the present invention but merely to exemplify various modifications of the described additives within the scope of the present invention.

Example 1

[Inhibitory Effect of Bacteriocin Culture on Helicobacter Pylori]

Helicobacter pylori HP24 isolated from the Helicobacter pylori ATCC 43579, ATCC 4867, DSM 10242, DSM 9691 and biopsy tissue of duodenal ulcer patients as known methods (Catholic University Medical Department, 44, 3, 739 (1991)). Antimicrobial tests were carried out on the bacteria, HP37 and HP54. The culture of Helicobacter pylori was cultured using a well-known method, that is, Brucella medium and the like at 37 ℃, aerobic conditions. Bacteriocin cultures were cultured (Lactococcus lactis subspisis lactis A164 (strain of patent application No. 98-40669, pending patent application No. 98-40669 by the same applicant) in the same manner as previously known methods (culture 16 hours) The filtrate was prepared by aseptic filtration. The starter prepared by pre-culturing the Helicobacter pylori was inoculated in Helicobacter pylori medium at 5.0% by weight, and then the bacteriocin culture medium was added by weight percent concentration to compare the bacterial count after 3 hours of culture.

As shown in Table 1, compared with the addition of the bacteriocin culture, the addition group was confirmed to exhibit an inhibitory effect on not only Helicobacter pylori standard strains, but also clinical isolates, and Helicobacter pylori bacteria were found not to proliferate and die. Could.

By using this killing effect of bacteriocin it was confirmed that it can be used as a good treatment for gastrointestinal diseases caused by Helicobacter pylori.

Example 2

[Production of bacteriocin composition]

Bacteriocin compositions were prepared in various forms using Lactococcus lactis subspiris Lactis A164 cultures (bacteriocin-containing cultures). That is, the bacteriocin composition obtained by pure purification using a known bacteriocin purification method (composition a), the culture medium was centrifugally filtered at 10,000 rpm for 10 minutes to remove the cells, and then the culture filtrate was freeze-dried as in the known method. Using the composition (composition b), the powder bacteriocin composition (composition c) obtained by directly lyophilizing the culture solution containing the cells, the known spray drying method (for example, using skim milk powder as a binder), Each powder bacteriocin composition (composition d, composition e) obtained by spray drying in a state of removing or containing cells was prepared.

Table 2 lists the component contents for each of the above compositions.

¹⁾ means purified bacteriocin powder.

²⁾ As a culture product produced by lactic acid bacteria, it refers to organic acids and medium components such as lactic acid.

Example 3

[Effect of Helicobacter Pylori Inhibition by Bacteriocin Composition]

Inhibition of the bacteriocin composition was performed on two representative strains of relatively high resistance among the above Helicobacter pylori standard strains and clinical isolates. That is, each powder composition was dissolved in sterile water relative to the content of bacteriocin, and the growth inhibition was confirmed in the same manner as in Example 1.

As shown in Tables 3 and 4, it was confirmed that the bacteriocin composition effectively inhibited the growth of the Helicobacter pylori DSM10242 strain and the HP54 strain, respectively.

As a result of administering each bacteriocin composition relative to the bacteriocin content, the bacteriocin content was confirmed to be effective at 0.1 ppm, and at 1 ppm or more, a clear inhibitory effect was confirmed. That is, it was confirmed that the bacteriocin composition can be used as an appropriate composition for treating gastrointestinal diseases by enabling the suppression of growth of Helicobacter pylori bacteria.

Example 4

[Effect of Gastrointestinal Disease Improvement by Animal Experiment]

In order to confirm the treatment and improvement effect of gastrointestinal diseases, the mouse model was used to check the inhibition of Helicobacter pylori. Mouse models can predict in vivo activity against Helicobacter pylori in humans, see Jenks (Antimicrobial agents and Chemotherapy, Apr, 777 (1999)) and Lee et al. Gastroenterology, 99, 1315 (1990). It was carried out by. In other words, Sprague-Dawley (SD) rat male (90-100 g body weight) purchased from the Korean Experimental Animal Center was injected with 0.5 ml of cultured Helicobacter pylori DSM 10242 and fasted for 12 hours. After infection three times a day for one week, 10 mg of bacteriocin composition b was administered two weeks after the last administration. After 3 weeks of administration, the rats were killed and then the stomach was excised. Remove the chromosomes from the pyloric copper area above, chop them and place them in a reagent containing urease. The presence of Helicobacter pylori changed to purple (alkaline), and Helicobacter pylori was positive.

Table 5 shows the results of these animal experiments, which were determined to be Helicobacter pylori negative in all rats (10) used in the experiment.

These results are believed to prove that the bacteriocin composition according to the present invention has a function of effectively inhibiting or killing Helicobacter pylori bacteria. In addition, when animal experiments predict human experiments, it is judged that it is possible to effectively improve and treat gastrointestinal diseases caused by Helicobacter pylori.

The bacteriocin natural antimicrobial composition developed by the present invention is a natural protein component, which not only ensures stability in the body even after ingestion for a long time, but also effectively inhibits Helicobacter pylori bacteria causing gastrointestinal diseases, thereby improving gastrointestinal disease and It can be used as a therapeutic agent.

Claims (5)

delete Bacteriocin Production Strain Lactococcus Lactis Subsurfis Lactis A164 (Strain of KFCC 11047, Accession No. 98-40669, pending patent application of the Republic of Korea by the same applicant) Bacteriocin-producing strain culture 0.1-10.0 wt. % Or 2-100% by weight of the bacteriocin produced by this strain, gastrointestinal disease improvement natural antibacterial substance composition using bacteriocin. delete delete delete